November 2, 2026 · Annals of internal medicine · DOI: 10.7326/ANNALS-26-04072-JC

In T2D, combined SGLT2i + GLP-1 RA vs. either alone does not reduce MACE or renal outcomes.

Listen to this summary

This Annals of Internal Medicine article appears to ask whether adding a GLP-1 receptor agonist to an SGLT2 inhibitor, compared with either drug alone, reduces major adverse cardiovascular events (MACE) or kidney outcomes in adults with type 2 diabetes. The authors' conclusion, as stated in the title, is that the combination offers no such benefit. The abstract provided is only a placeholder, so these findings are drawn from the title and not from the study's methods or data.

Aviva Atri-Schuller, Victor M Montori

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play